Press Releases

CORONA DEL MAR, Calif.--(BUSINESS WIRE)--

The Foundation to Eradicate Duchenne (FED), the CureDuchenne Foundation, AVI BioPharma and Prosensa will host an Exon Skipping Conference for Duchenne Muscular Dystrophy from October 14 -17, 2008 at the Banbury Center of Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. Participants are being drawn from a wide area of research, from chemistry to regulatory authorities, to critically review progress on oligonucleotides as therapeutic agents for Duchenne Muscular Dystrophy.

Over the past years, there have been advances in nucleotide chemistry that have led to oligonucleotides (exon skipping compounds) that retain sequence-specific anti-sense activity, while showing little or no protein binding or associated off-target effects. Additional developments in chemistry have improved intracellular delivery, allowing more potent small molecules showing biochemical efficacy in a larger variety of tissues and cells. Recent studies suggest that many hurdles previously inhibiting movement of anti-sense drugs into clinics and standard of care have now been overcome.

The goal is to end the meeting with a more clear understanding of the hurdles that remain in using oligonucleotides as therapeutic agents and to highlight research strategies that are likely to produce positive outcomes.

This conference is being organized by Adrian Krainer, Ph.D., Professor, Banbury Center of Cold Harbor Laboratory; Eric Hoffman,Ph.D, Center Director, Center for Genetic Medicine Research, Children's National Medical Center; and Terence A. Partridge, Ph.D., Principal Investigator, Children's Research Institute, Center for Genetic Medicine Research, Children's National Medical Center

    Participation is by invitation only.

    About Duchenne Muscular Dystrophy (DMD)

One in every 3,500 boys worldwide is afflicted with Duchenne muscular dystrophy. They will be in wheel chairs by 12 and, historically, most have not survived their teenage years. Duchenne knows no boundaries and crosses all cultures and races. It can happen in any family. There currently is no cure, but for the first time, there are promising therapies on the horizon.

About The Foundation to Eradicate Duchenne (FED)

The Foundation to Eradicate Duchenne was established by Dana and Joel Wood of Alexandria, Virginia. Their son James Wood was diagnosed in May 2000 with Duchenne Muscular Dystrophy. The Woods are both lobbyists in Washington, D.C., and have devoted much of their time and energies to this cause, working with others to achieve millions of dollars in federal earmarks for Duchenne research and a significant increase in the attention devoted to Duchenne at the National Institutes of Health. For more information on FED, please visit www.duchennemd.org.

About CureDuchenne

CureDuchenne is a non-profit organization founded in 2003 by Debra and Paul Miller, parents of a Duchenne boy. CureDuchenne's Vision is its name...to cure Duchenne muscular dystrophy. CureDuchenne aggressively seeks the most promising, leading edge research breakthroughs and expedites them to the clinical trial process. The ultimate goal...give the boys that have Duchenne now a chance to live a normal life by expediting the availability of treatments/therapies and or a cure that can give quality of life to Duchenne boys, much like insulin does for diabetics. For more information about CureDuchenne, please visit www.cureduchenne.org email debra@cureduchenne.org.

About Prosensa

Prosensa is a Dutch biopharmaceutical company dedicated to the development of RNA based therapeutics targeting diseases with unmet medical needs, in particular neuromuscular disorders. Prosensa's drug development is based upon a unique and proprietary technology platform involving 'exon skipping', enabling correction of mutated RNA. This ability to modulate genes selectively through RNA-based therapeutics could provide a new way to treat a wide range of human diseases. The company has, together with its partner LUMC, a leadership position in fundamental patents, technology, and know-how relating to RNA-based approaches and exon skipping. Prosensa's lead compound for DMD is currently in clinical phase I/II development and the company has received orphan drug designation both in Europe and the U.S.A. Prosensa is elected the European Venture Company of 2007. For more information on Prosensa, please visit www.prosensa.nl.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based drugs using the company's expanded portfolio of proprietary antisense compounds (PMOs). The company's technology applications leverage distinct mechanisms of action in a range of genetic diseases, genetic disorders and the genetic code of disease-causing organisms. The emerging field of directed alternative RNA splicing represents AVI's newest and most exciting application based on the company's core antisense technology. Functional attributes of this approach may include correcting genetic defects (RNA mutations; which AVI believes could produce promising treatments for Duchenne muscular dystrophy), coding for novel soluble receptors (an exciting and novel approach which could have application in the treatment of inflammatory diseases such as rheumatoid arthritis), and the reduction in activity of immune modulators in disease states (currently being applied to IL-10). AVI's RNA-based drug programs also include blocking mRNA translation. More information about AVI is available at www.avibio.com.

Source: CureDuchenne

DUBLIN, Ireland--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/c12d09/rubber_chemicals_w) has announced the addition of the "Rubber Chemicals World Data Book 2007" report to their offering.

Rubber Chemicals World Data Book 2007 provides an up-to-date and comprehensive overview of the $3.1 billion global market for organic rubber processing chemicals. Though used in small quantities, these chemicals are essential to rubber compounding, where they control vulcanization, ease processing and improve the physical properties of the final product. Materials covered include antioxidants, antiozonants, accelerators, waxes, adhesion promoters and other products (retarders/antiscorch agents, antireversion agents, curing agents, tackifiers, peptizers, foaming and blowing agents and flame retardants). The report provides coverage for all regions and 24 leading countries. Data are presented for all years from 1996 through 2006, with forecasts provided for 2007, 2008, 2009, 2010, 2015 and 2025. The report includes profiles of 63 leading suppliers, providing intelligence on capacity, product mix, annual rubber chemical sales and recent restructuring activities.

    Major additions to this version include:

    --  Short term forecasts (2008-2010) as well as long term
        forecasts through 2015 and 2025;

    --  Current production capacity for antioxidants (6PPD & TMQ) and
        accelerators by company;

    --  Market share for leading suppliers by region and product
        segment;

    --  The latest information on industry restructuring;

    --  Additional and expanded company profiles for both leading and
        niche suppliers, including many Chinese companies;

    --  A separate Excel file containing the report's statistical data
        and capacity figures in spreadsheet form.

Key Topics Covered:

1. Executive Summary & Key Statistics
- Rubber Chemical Market - Current Trends & Conditions
- Ten Leading Rubber Chemical Consuming Countries
- Rubber Chemicals Suppliers & Market Share

2. Overview
- What are Rubber Chemicals?
- Pricing Trends
- Research & Technology
- Legal, Regulatory & Environmental Issues
- Overview of the Rubber & Tire Sectors

3. Rubber Chemical Demand by Type & Market
- Rubber Chemical Types
- Antidegradants, continued
- Accelerators
- Other Rubber Chemicals
- Rubber Chemical Markets

4. Rubber Chemicals Demand by Region & Country
- World Rubber Chemical Demand
- North America
- European Union 25
- Asia
- South America
- Eastern Europe
- Africa & the Middle East

5. Suppliers, Capacity & Market Share
- Industry Participants & Concentration Levels
- Company Sales, Capacity & Market Share
- Acquisitions & Restructuring
- Supplier Profiles

Companies Mentioned:

- Anshan City Xinda Chemical Co., Ltd.
- Arkema Group
- Bann Quimica Limitada
- Chanzhou Huamei Fine Chemicals Co., Ltd.
- Chemtura Corporation
- Ciba Specialty Chemicals Inc.
- Cytec Industries, Inc.
- Danyang Kangpudun Zhonghuajian Chemical Industry Co., Ltd.
- DC Chemical Co., Ltd.
- Duslo AS (including Istrochem)
- Eliokem SAS
- Emerald Performance Materials (formerly Noveon)
- Flexsys NV (subsidiary of Solutia)
- General Quimica SA
- Goodyear Tire & Rubber Company
- Hai'an Feiya Chemical Industry Co., Ltd.
- Hebi Huaxia Auxiliary (Accelerator) Co., Ltd.
- Hebi No.1 Rubber Additives Plant
- Henan Huaxian Chemical Plant Co., Ltd.
- Henan Tangyin Yongxin Auxiliary Agent Factory Co., Ltd.
- INDSPEC Chemical Corporation
- Kawaguchi Chemical Industry Co., Ltd.
- Ke Mai (Tianjin) Chemical Technical Co., Ltd.
- Kemerovo JSC "AZOT"
- Korea Kumho Petrochemical Co., Ltd.
- Lanxess GmbH
- Linkwell Rubber Chemicals (Qingdao) Co., Ltd.
- Melamin D.D. Kocevje
- Merchem Limited
- MLPC International
- Nanjing Chemical Industry Corporation
- NOCIL - National Organic Chemical Industries Ltd.
- Northeast Auxiliary Chemical Industry Co., Ltd.
- OM Group Inc.
- Ouchishinko Chemical Industrial Co., Ltd.
- PMC Group International (formerly ICI India Limited)
- Puyong Willing Chemicals Co., Ltd.
- Rockwood Specialties Group, Inc. (Chemetall GmbH)
- Rongcheng Tianyu Technology Co., Ltd.
- Sanshin Chemical Industry Co., Ltd.
- Schill + Seilacher AG (Struktol Company of America)
- Seiko Chemical Co., Ltd.
- Shandong Feida Chemical Science & Technology, Co., Ltd.
- Shandong Shanxian Chemicals Co., Ltd.
- Shandong Yanggu Huatai Chemical Co., Ltd.
- Shanghai Dunhuang Chemical Plant Co., Ltd.
- Shepherd Chemical Company
- SI Group, Inc. (formerly Schenectady International)
- Sinorgchem Group Co. (Shandong Sinorgchem Company)
- Sumitomo Chemical Co., Ltd.
- Taminco N.V.
- Tianjin No.1 Organic Chemical Plant
- Tongling Chemical Industry Group Corporation
- Total S.A. (Sartomer Company & Cray Valley)
- United Rubber Chemical Co., Ltd.
- RT Vanderbilt Company, Inc.
- Volzhsky Orgsynthese, JSC
- Western Reserve Chemical Corp. & Qingdao Auxiliary Chemical Co., Ltd
- Zhejiang Ultrafine Powders & Chemicals Co., Ltd. (Leqing Ultramicron
  Chemical Co., Ltd.)
- Zhejiang Yongjia Chemical Plant Co., Ltd.
- Zhenjiang Zhenbang Chemical Industry Co., Ltd. (Zhenjiang No.2
  Chemical Factory)
- Zhuzhou Tiancheng Chemicals Co., Ltd.
- Zibo Huamei Chemical Co., Ltd. (formerly Shandong Sanyi Fine
  Chemical Co., Ltd.)


    For more information visit
http://www.researchandmarkets.com/research/c12d09/rubber_chemicals_w

Source: Research and Markets Ltd.

There's nothing worse than a filthy car. Apart from one's home, a person's automobile is likely their biggest single investment, so it's amazing how few people really know how to keep their cars looking showroom new.

"Washing your car doesn't have to be a major chore," says Michael L. Metter, President and CEO of SpongeTech(R) Delivery Systems, Inc., a New York-based company that creates revolutionary cleaning products for cars, canines, and kids. Waxing philosophical, Metter offers the following tips for giving your car a spotless sponging down:

    --  Wash Your Car Regularly!: Bug and bird droppings, dirt, and
        salt can cause corrosion if left unattended, so give your car
        a proper wash at least twelve times a year. Bird droppings are
        highly acidic, so the longer their leavings are left on your
        hood, the more damage they'll cause to your paint job.

    --  Don't Just Wash, Wax!: Wax sealants help protect paint from
        scratches and damage from chemicals, keeps paint from fading,
        and keep your car looking shiny.

    --  Respect The Beltline!: Since scratchy silicone and salt tend
        to accumulate below the beltline (approximately the middle of
        the side of the vehicle), particularly during winter months,
        it's advisable to wash one section of the car at a time so as
        not to redistribute dirt and grit to the top, hood, or trunk
        of your car.

    --  Towel Off!: One of the most important parts of the entire
        process, improper drying can lead to water spots, streaks, and
        scratches. Use 100% cotton towels to avoid scratching. Work
        from the top down, gently blotting, not wiping, water from the
        surface.

    --  Kick The Bucket!: Wash and wax your vehicle to a professional
        finish in less than thirty minutes with the original
        SpongeTech(R), an exciting new cleaning product with soaps,
        shampoos, and waxes already built in!

The company's patented super-absorbent polymer sponges are loaded with specially formulated soaps and waxes that are released when the sponge is dampened and applied to surfaces with minimal pressure. With SpongeTech(R), car lovers will never have to hassle with buckets and bottles again!

"We're also exploring the possibility of using its patented technology for other uses," says Mr. Metter. "These include pharmaceutical applications; as well as anti-bacterial, bath, and kitchen soaps for household uses." For more information visit www.spongetech.com.

Source: SpongeTech(R) Delivery Systems, Inc.

SHANGHAI, China, Oct. 14 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced preliminary selected unaudited financial results for the third quarter ended September 30, 2008, and updated its guidance for the full year 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Third Quarter 2008 Preliminary Unaudited Financial Results

For the third quarter ended September 30, 2008, WuXi reports the following preliminary unaudited financial results. These results are subject to change as a result of finalization of share-based compensation expenses, closing adjustments and completion of the review process for the quarter.

               Preliminary Third Quarter 2008 Financial Results
                    (Unaudited, U.S. Dollars in Millions)

                                 GAAP                      Non-GAAP
                         The third quarter of        The third quarter of
                           2008      2007    %        2008       2007    %
                                          Growth*                      Growth*
    Net Revenue       $66.0 - 67.5  $34.0    96%  $66.0 - 67.5  $34.0    96%
      Laboratory
       Services        46.0 - 47.0   26.7    74%   46.0 - 47.0   26.7    74%
      Manufacturing
       Services        20.0 - 20.5    7.3   177%   20.0 - 20.5    7.3   177%

    Gross Profit       21.4 - 22.9   16.0    38%   25.9 - 27.4   16.3    63%
      Laboratory
       Services        18.7 - 19.7   12.9    49%   22.0 - 23.0   13.2    70%
      Manufacturing
       Services         2.7 -  3.2    3.1    (5%)   3.9 -  4.4    3.1    34%

    Operating Income    6.7 -  8.2    7.5    (1%)  13.7 - 15.2    9.0    61%

    EBITDA             13.9 - 15.4   10.2    44%   17.0 - 18.5   11.7    52%

    * Growth rate calculated based on mid-point range

Financial data presented on a non-GAAP basis exclude share-based compensation expenses and amortization of acquired intangible assets. The non-GAAP measures are reconciled to the corresponding GAAP measures in the section below titled "Use of Non-GAAP Financial Measures".

Commenting on the third quarter 2008 preliminary results, Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech, said, "WuXi continues its historical trend of delivering strong revenue and profitability growth, as reflected in the 96% top-line revenue and 52% non-GAAP EBITDA growth (each using the mid-point of current estimates). As we enter the fourth quarter, we expect lower than anticipated full-year 2008 revenues, due to cancelled or delayed projects from small biotechnology customers. However, our China-based laboratory services business remains strong and is expected to grow over 40%, year-over-year.

"Even with the financial market unrest, we believe the need for outsourced services remains robust. WuXi has an outstanding reputation for providing high-quality, IP-protected services in a cost-effective and efficient manner. In all environments, we are positioned to meet and anticipate our customer needs, by expanding and evolving our services, while maintaining our focus on revenue growth and profitability."

Expected third quarter 2008 operating income reflects expected sales, general and administrative expenses (excluding share-based compensation) generally consistent with the second quarter of 2008.

On November 12, 2008, WuXi expects to announce finalized operating results (including net income and earnings per ADS) for the third quarter 2008. In the interim, WuXi is evaluating and/or finalizing the following items, which impact net income and earnings per ADS: its goodwill balances from the AppTec acquisition for impairment and income tax provisions.

Revised Full Year 2008 Guidance

In light of the current economic environment and its impact on the anticipated research and development spending of its smaller customers, WuXi is revising its net revenue guidance for the full year 2008 to $260 to $265 million from $280 to $300 million. This represents year-over-year revenue growth ranging from 92% to 96%. Full year non-GAAP EBITDA will be in the range of $70 to $75 million (excluding share-based compensation charges, potential impact from goodwill impairment charges, and further mark-to-market adjustment on foreign currency forward contracts).

Termination of Rule 10b5-1 Trading Plans; Company Trading Window

At this time, each of our four founders (including Dr. Li) and other management members are terminating their existing 10b5-1 plans.

A number of our executive officers, other management team members and employees, including each of our four founders (who are also WuXi executive officers and directors), previously (i) established pre-arranged stock trading plans in accordance with the provisions of Rule10b5-1 of the Securities Exchange Act of 1934, and (ii) sold ADSs pursuant to those plans.

Although those 10b5-1 plans were terminated, we expect up to 350,000 ADSs may be sold by other management members and employees prior to year-end for 409A purposes. Prior to 2008, a number of our management members and employees who were U.S. taxpayers were granted options with an exercise price potentially below fair market value on the date of grant, as determined under Section 409A of the U.S. Tax Code. To avoid the adverse tax consequences imposed under Section 409A to these U.S. taxpayers, the options were amended previously to require that they be exercised, if at all, on or prior to December 31, 2008 (no other changes were made). If unexercised by year-end those options will expire, and those individuals may need to sell ADSs to pay related taxes and the purchase price payable upon exercise.

Following the release of this announcement and the related conference call, WuXi intends to open its trading window under WuXi's Insider Trading Policy.

Conference Call

Following this announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (Eastern) / 5:00 am (Pacific) / 8:00 pm (Beijing/Hong Kong) on October 14, 2008 to discuss the preliminary 2008 third quarter financial results. The conference call may be accessed by calling (US) +1 866-239-0753 or +1 718-354-1157 / (HK) +852-3002-1615 or 800-933-519 / (UK) 0800-559-3272. Passcode: 5190406.

A live webcast of the conference call and replay will be available on the investor relations page of WuXi PharmaTech's website at http://www.wuxiapptec.com .

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

Use of Non-GAAP Financial Measures

We have provided the preliminary unaudited third quarter 2008 and third quarter 2007 financial data and EBITDA on a non-GAAP basis, which excludes share-based compensation expenses and amortization of acquired intangible assets. We believe both management and investors benefit from referring to EBITDA and these non-GAAP financial measures in assessing our financial performance and liquidity and when planning and forecasting future periods. EBITDA and these non-GAAP operating measures are useful for understanding and assessing underlying business performance and operating trends. You should not view non-GAAP (including EBITDA) results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies, and should refer to the reconciliation of non-GAAP measures to GAAP measures for the indicated periods attached hereto.

                        RECONCILIATION OF NON-GAAP TO GAAP
                      (Unaudited, U.S. Dollars in Millions)

                                  The third quarter of 2008
                                                    Add:
                                      Add:      Amortization
                                  Share-based    of acquired
                                  compensation   intangible
                          GAAP      expenses       assets        Non-GAAP

    Net Revenue       $66.0 - 67.5  $    --       $    --       $66.0 - 67.5
     Laboratory
      Services         46.0 - 47.0                               46.0 - 47.0
     Manufacturing
      Services         20.0 - 20.5                               20.0 - 20.5

    Gross Profit       21.4 - 22.9      0.6           3.9        25.9 - 27.4
     Laboratory
      Services         18.7 - 19.7      0.6           2.7        22.0 - 23.0
     Manufacturing
      Services          2.7 -  3.2       --           1.2         3.9 -  4.4

    Operating
     Income             6.7 -  8.2      3.1           3.9        13.7 - 15.2

    EBITDA            $13.9 - 15.4     $3.1       $    --       $17.0 - 18.5



                                   The third quarter of 2007
                                                     Add:
                                     Add:       Amortization
                                  Share-based    of acquired
                                 compensation    intangible
                          GAAP      expenses        assets        Non-GAAP

    Net Revenue          $34.0      $    --       $      --         $34.0
     Laboratory
      Services            26.7           --              --          26.7
     Manufacturing
      Services             7.3           --              --           7.3

    Gross Profit          16.0          0.3                          16.3
     Laboratory
      Services            12.9          0.3              --          13.2
     Manufacturing
      Services             3.1           --              --           3.1

    Operating
     Income                7.5          1.5              --           9.0

    EBITDA               $10.2         $1.5        $     --         $11.7

Cautionary Note Regarding Forward-Looking Statements

Statements in this release contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995, including, among others, our preliminary financial unaudited results for the third quarter 2008; expected net revenue levels for 2008 and expected revenue trends related to our smaller biotech customers and the impact of current market turmoil; the global trend in R&D outsourcing; and our expected ability to grow revenue and profitability in 2008 and beyond and meet and anticipate customer needs in all environments while maintaining our ability to adjust our internal capacity.

These forward-looking statements are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. Our actual results and financial condition and other circumstances may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Our preliminary Q3 2008 operating results may change as a result of final management review, review by outside auditors, finalization of share-based compensation expenses and closing adjustments for the quarter. Also the uncertainty in the global economy may adversely impact our business and R&D outsourcing trends; and our smaller biotech customers may continue to face funding and other spending difficulties for longer than anticipated. We may be unable to successfully expand our capabilities to meet client needs. In addition other factors that could cause our actual results to differ from what we currently anticipate include our limited operating history; failure to generate sufficient future cash flows or secure any required future financing on acceptable terms or at all; failure to retain key personnel; effective integration of products and services from AppTec; our reliance on a limited number of customers to continue to account for a high percentage of our revenues; risk of payment failure by any of our large customers, which could significantly harm our cash flows and profitability; dependency upon the continued service of our senior management and key scientific personnel and ability to retain our existing customers or expand our customer base. The financial information contained in this release should be read in conjunction with the consolidated and pro forma financial statements and notes thereto included in our 2007 Annual Report on Form 20-F filed with available on the Securities and Exchange Commission's website at http://www.sec.gov . For additional information on these and other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 10 of our 2007 Annual Report on Form 20-F. Our preliminary results of operations for the third quarter 2008 are not necessarily indicative of our operating results for any future periods. Any projections in this release are based on limited information currently available to us, which is subject to change. Although these projections and the factors influencing them will likely change, we undertake no obligation to update or revise these forward- looking statements, whether as a result of new information, future events or otherwise, after the date of this press release. Such information speaks only as of the date of this release.

    For more information, please contact:

     Debra Yu, MD
     Vice President Strategy
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +1-215-218-5559
     Email: ir@wuxiapptec.com

     Dr. Hai Mi
     Executive Director of Investor Relations and Business Planning
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +86-21-5046-3726
     Email: ir@wuxiapptec.com

     Juliane Snowden
     Vice President of Investor Relations
     Burns McClellan
     Tel:   +1-212-213-0006
     Email: Jsnowden@burnsmc.com

SOURCE WuXi PharmaTech (Cayman) Inc.

BRIXEN, Italy--(BUSINESS WIRE)--

TTControl, TTTech's subsidiary for off-highway solutions, and HYDAC International, one of the leading companies in the area of fluid technology and hydraulics, announce their strategic partnership in the area of electronics for mobile equipment. This comprehensive cooperation will promote the further development and worldwide distribution of innovative solutions for the industry. The combination of HYDAC's professional sales network with TTControl's profound electronics expertise opens up significant growth potential.

The cooperation between TTControl and HYDAC will meet the growing demands of the dynamic market. Customers are more and more inclined to purchase electronics and hydraulics in combination. Established in 2001, TTControl has a broad range of highly reliable electronic control systems and a vast product offering related to mobile work machinery. The company's electronic units are used in a number of commercial off-highway projects, fulfilling the safety requirements of the international IEC 61508 standard up to SIL3 and achieving the EN ISO 13849 performance level e.

"What convinced us to work with TTControl, was the company's outstanding expertise in the area of electronics development", states Dr. Franz Josef Eckle, managing director of HYDAC Electronic GmbH in Saarbrucken. "In TTControl we have found a partner that can provide our customers with highly reliable, cost-effective and user-friendly solutions."

HYDAC's product offering ranges from hydraulic components through complex mechatronic drive units for mobile and stationary machines and systems. HYDAC is among the five leading hydraulics companies worldwide. Both companies expect considerable sales growth from the synergy of their cooperation.

HYDAC contributes its global sales network to the partnership. "HYDAC's extensive sales network provides us with the opportunity to bring our solutions closer to customers all around the world," states Marc Weissengruber, member of the managing board at TTControl. With 10 sales offices in Germany and more than 40 locations worldwide, HYDAC offers both global reach and local support.

Source: TTTech